Clinical Trials Browser

Phase 4 × ceritinib × 90 days × Clear all

NCT02584933 2026-02-03

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

Phase 4 Active not recruiting

Neoplasms